Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Endometrial Cancer-Pipeline Review, H2 2016

Endometrial Cancer-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Endometrial Cancer-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer-Pipeline Review, H2 2016, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 35, 17, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.Endometrial Cancer.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 6

Endometrial Cancer Overview 7

Therapeutics Development 8

Endometrial Cancer-Therapeutics under Development by Companies 10

Endometrial Cancer-Therapeutics under Investigation by Universities/Institutes 13

Endometrial Cancer-Pipeline Products Glance 14

Endometrial Cancer-Products under Development by Companies 17

Endometrial Cancer-Products under Investigation by Universities/Institutes 21

Endometrial Cancer-Companies Involved in Therapeutics Development 22

Endometrial Cancer-Therapeutics Assessment 67

Drug Profiles 83

Endometrial Cancer-Dormant Projects 384

Endometrial Cancer-Discontinued Products 387

Endometrial Cancer-Product Development Milestones 388

Appendix 403

List of Figures

Number of Products under Development for Endometrial Cancer, H2 2016 16

Number of Products under Development for Endometrial Cancer-Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Products, H2 2016 24

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Top 10 Targets, H2 2016 77

Number of Products by Stage and Top 10 Targets, H2 2016 77

Number of Products by Top 10 Mechanism of Actions, H2 2016 82

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 82

Number of Products by Top 10 Routes of Administration, H2 2016 87

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 87

Number of Products by Top 10 Molecule Types, H2 2016 89

Number of Products by Stage and Top 10 Molecule Types, H2 2016 89

List of Tables

Number of Products under Development for Endometrial Cancer, H2 2016 16

Number of Products under Development for Endometrial Cancer-Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Development by Companies, H2 2016 (Contd..1) 19

Number of Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Late Stage Development, H2 2016 22

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Endometrial Cancer-Pipeline by Ability Pharmaceuticals, S.L., H2 2016 30

Endometrial Cancer-Pipeline by Advenchen Laboratories, LLC, H2 2016 31

Endometrial Cancer-Pipeline by Aeterna Zentaris Inc., H2 2016 32

Endometrial Cancer-Pipeline by ArQule, Inc., H2 2016 33

Endometrial Cancer-Pipeline by AstraZeneca Plc, H2 2016 34

Endometrial Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 35

Endometrial Cancer-Pipeline by BeiGene, Ltd., H2 2016 36

Endometrial Cancer-Pipeline by BioNTech AG, H2 2016 37

Endometrial Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2016 38

Endometrial Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2016 39

Endometrial Cancer-Pipeline by Cellceutix Corporation, H2 2016 40

Endometrial Cancer-Pipeline by Critical Outcome Technologies Inc, H2 2016 41

Endometrial Cancer-Pipeline by Eisai Co., Ltd., H2 2016 42

Endometrial Cancer-Pipeline by Eli Lilly and Company, H2 2016 43

Endometrial Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 44

Endometrial Cancer-Pipeline by Exelixis, Inc., H2 2016 45

Endometrial Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 46

Endometrial Cancer-Pipeline by Galena Biopharma, Inc., H2 2016 47

Endometrial Cancer-Pipeline by GamaMabs Pharma S.A., H2 2016 48

Endometrial Cancer-Pipeline by Genmab A/S, H2 2016 49

Endometrial Cancer-Pipeline by GlaxoSmithKline Plc, H2 2016 50

Endometrial Cancer-Pipeline by Gradalis Inc., H2 2016 51

Endometrial Cancer-Pipeline by Horizon Pharma Plc, H2 2016 52

Endometrial Cancer-Pipeline by Immunocore Ltd, H2 2016 53

Endometrial Cancer-Pipeline by ImmunoGen, Inc., H2 2016 54

Endometrial Cancer-Pipeline by Incyte Corporation, H2 2016 55

Endometrial Cancer-Pipeline by Innate Pharma S.A., H2 2016 56

Endometrial Cancer-Pipeline by Karyopharm Therapeutics, Inc., H2 2016 57

Endometrial Cancer-Pipeline by Merck & Co., Inc., H2 2016 58

Endometrial Cancer-Pipeline by Merck KGaA, H2 2016 59

Endometrial Cancer-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 60

Endometrial Cancer-Pipeline by Novartis AG, H2 2016 61

Endometrial Cancer-Pipeline by OncoHoldings, Inc., H2 2016 62

Endometrial Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 63

Endometrial Cancer-Pipeline by Pfizer Inc., H2 2016 64

Endometrial Cancer-Pipeline by Pharma Mar, S.A., H2 2016 65

Endometrial Cancer-Pipeline by Pharmsynthez, H2 2016 66

Endometrial Cancer-Pipeline by Pivot Pharmaceuticals Inc, H2 2016 67

Endometrial Cancer-Pipeline by Puma Biotechnology, Inc., H2 2016 68

Endometrial Cancer-Pipeline by Sanofi, H2 2016 69

Endometrial Cancer-Pipeline by Shenogen Pharma Group Ltd, H2 2016 70

Endometrial Cancer-Pipeline by Sigma-Tau S.p.A., H2 2016 71

Endometrial Cancer-Pipeline by Synthon Holdings BV, H2 2016 72

Endometrial Cancer-Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 73

Endometrial Cancer-Pipeline by Vyriad Inc, H2 2016 74

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Stage and Target, H2 2016 78

Number of Products by Stage and Mechanism of Action, H2 2016 83

Number of Products by Stage and Route of Administration, H2 2016 88

Number of Products by Stage and Molecule Type, H2 2016 90

Endometrial Cancer-Dormant Projects, H2 2016 392

Endometrial Cancer-Dormant Projects (Contd..1), H2 2016 393

Endometrial Cancer-Dormant Projects (Contd..2), H2 2016 394

Endometrial Cancer-Discontinued Products, H2 2016 395

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ability Pharmaceuticals, S.L., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene, Ltd., BioNTech AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellceutix Corporation, Critical Outcome Technologies Inc, Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., GamaMabs Pharma S.A., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., Horizon Pharma Plc, Immunocore Ltd, ImmunoGen, Inc., Incyte Corporation, Innate Pharma S.A., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals Inc, Novartis AG, OncoHoldings, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharma Mar, S.A., Pharmsynthez, Pivot Pharmaceuticals Inc, Puma Biotechnology, Inc., Sanofi, Shenogen Pharma Group Ltd, Sigma-Tau S.p.A., Synthon Holdings BV, Vertex Pharmaceuticals Incorporated, Vyriad Inc

Endometrial Cancer Therapeutic Products under Development, Key Players in Endometrial Cancer Therapeutics, Endometrial Cancer Pipeline Overview, Endometrial Cancer Pipeline, Endometrial Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com